Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease - PubMed (original) (raw)
Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease
P Teismann et al. Synapse. 2001 Feb.
Abstract
To study the possible role of the isoenzymes of cyclooxygenase COX-1 and COX-2 in the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of Parkinson's disease we used acetylsalicylic acid, a COX-1/COX-2 inhibitor, in comparison with meloxicam, a preferential COX-2 inhibitor. As markers of protection we determined the effects on MPTP-induced striatal dopamine depletion, locomotor activity, cell loss, and tyrosine hydroxylase immunoreactivity (TH-IR) in the substantia nigra pars compacta. Male C57BL/6 mice (n = 82) were treated with a single dose of acetylsalicylic acid (10, 50, 100 mg/kg i.p.) or meloxicam (2, 7.5, 50 mg/kg i.p.) immediately prior to administration of MPTP (30 mg/kg s.c.) or saline. After 7 days the mice were sacrificed to analyze striatal dopamine and metabolite levels. Nigral sections were processed for Nissl-staining and TH-IR. In the saline-treated MPTP control group striatal dopamine levels were reduced to 15.9% of control values. Dopamine depletion was significantly attenuated to values of 37.1 and 38.6% of saline control values by acetylsalicylic acid (50 and 100 mg/kg) and to values of 36 and 40% by meloxicam (7.5 and 50 mg/kg), respectively. MPTP-induced decrease of locomotor activity was significantly attenuated by acetylsalicylic acid and meloxicam. Remarkably, the MPTP-induced decrease of TH-IR as well as the loss of nigral neurons was nearly completely prevented by acetylsalicylic acid (100 mg/kg) and meloxicam (7.5 and 50 mg/kg). In conclusion, the inhibition of either COX-1/COX-2 by acetylsalicylic acid or preferentially COX-2 by meloxicam provided a clear neuroprotection against MPTP-toxicity on the striatal and nigral levels.
Similar articles
- Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease.
Schmidt N, Ferger B. Schmidt N, et al. Synapse. 2001 Apr;40(1):47-54. doi: 10.1002/1098-2396(200104)40:1<47::AID-SYN1025>3.0.CO;2-S. Synapse. 2001. PMID: 11170221 - Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Kupsch A, Sautter J, Götz ME, Breithaupt W, Schwarz J, Youdim MB, Riederer P, Gerlach M, Oertel WH. Kupsch A, et al. J Neural Transm (Vienna). 2001;108(8-9):985-1009. doi: 10.1007/s007020170018. J Neural Transm (Vienna). 2001. PMID: 11716151 - Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
Araki T, Muramatsu Y, Tanaka K, Matsubara M, Imai Y. Araki T, et al. Neurosci Lett. 2001 Oct 12;312(1):50-4. doi: 10.1016/s0304-3940(01)02176-0. Neurosci Lett. 2001. PMID: 11578843 - COX-2 and neurodegeneration in Parkinson's disease.
Teismann P, Vila M, Choi DK, Tieu K, Wu DC, Jackson-Lewis V, Przedborski S. Teismann P, et al. Ann N Y Acad Sci. 2003 Jun;991:272-7. doi: 10.1111/j.1749-6632.2003.tb07482.x. Ann N Y Acad Sci. 2003. PMID: 12846993 Review. - Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease.
Meissner W, Prunier C, Guilloteau D, Chalon S, Gross CE, Bezard E. Meissner W, et al. Mol Neurobiol. 2003 Dec;28(3):209-18. doi: 10.1385/MN:28:3:209. Mol Neurobiol. 2003. PMID: 14709785 Review.
Cited by
- Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease.
Vijitruth R, Liu M, Choi DY, Nguyen XV, Hunter RL, Bing G. Vijitruth R, et al. J Neuroinflammation. 2006 Mar 27;3:6. doi: 10.1186/1742-2094-3-6. J Neuroinflammation. 2006. PMID: 16566823 Free PMC article. - Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis.
Gagne JJ, Power MC. Gagne JJ, et al. Neurology. 2010 Mar 23;74(12):995-1002. doi: 10.1212/WNL.0b013e3181d5a4a3. Neurology. 2010. PMID: 20308684 Free PMC article. Review. - Aqueous extract from the Withania somnifera leaves as a potential anti-neuroinflammatory agent: a mechanistic study.
Gupta M, Kaur G. Gupta M, et al. J Neuroinflammation. 2016 Aug 22;13(1):193. doi: 10.1186/s12974-016-0650-3. J Neuroinflammation. 2016. PMID: 27550017 Free PMC article. - Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts.
Fellner L, Jellinger KA, Wenning GK, Stefanova N. Fellner L, et al. Acta Neuropathol. 2011 Jun;121(6):675-93. doi: 10.1007/s00401-011-0833-z. Epub 2011 May 12. Acta Neuropathol. 2011. PMID: 21562886 Free PMC article. Review. - Reversible Pharmacological Induction of Motor Symptoms in MPTP-Treated Mice at the Presymptomatic Stage of Parkinsonism: Potential Use for Early Diagnosis of Parkinson's Disease.
Khakimova GR, Kozina EA, Kucheryanu VG, Ugrumov MV. Khakimova GR, et al. Mol Neurobiol. 2017 Jul;54(5):3618-3632. doi: 10.1007/s12035-016-9936-9. Epub 2016 May 19. Mol Neurobiol. 2017. PMID: 27194433
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous